Next Article in Journal
Role of NK Cells in Cancer and Immunotherapy
Previous Article in Journal
Radiotheranostic Agents Targeting Neuroblastoma: State-of-the-Art and Emerging Perspectives
Review

Non-Coding RNAs and Wnt/β-Catenin Signaling Pathway in Gastric Cancer: From EMT to Drug Resistance

1
Disciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de São Paulo, São Paulo 04023-900, Brazil
2
Departamento de Patologia, Universidade Federal de São Paulo, São Paulo 04023-062, Brazil
3
Disciplina de Gastroenterologia, Departamento de Medicina, Universidade Federal de São Paulo, São Paulo 04023-062, Brazil
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Fred Saad and Danny N. Dhanasekaran
Onco 2021, 1(2), 140-157; https://doi.org/10.3390/onco1020012
Received: 12 October 2021 / Revised: 22 November 2021 / Accepted: 23 November 2021 / Published: 25 November 2021
Gastric cancer is one of the leading causes of cancer-related death worldwide. Although the treatment of gastric cancer patients has improved during the last decades, survival rates are still around 20%. Non-coding RNAs were shown to participate in numerous pathways during the development and progression of gastric cancer. MicroRNAs and lncRNAs are among the most well studied classes of non-coding RNAs, since they have important roles as oncogenic or tumor suppressor molecules in several pathways. The Wnt/β-catenin signaling pathway was proven to be critical in different contexts in cell biology and may help in prognosis and diagnosis of gastric cancer.
Gastric cancer is one of the most common cancers and the third cause of cancer-related death worldwide. The treatment of GC patients improved due to advancements in surgery, radiotherapy and chemotherapy. However, the long-term survival rate of patients with gastric cancer remains around 20%. Thus, development of novel therapeutic approaches is of great interest, in order to reduce the need for mutilating surgeries and morbid adjuvant therapies. For many years, it was believed that the RNA was a mere intermediate molecule in the genetic information flow. However, during the past decades, with the advent of new sequencing technologies, it was revealed that non-coding RNAs play important roles in many different biological processes. The Wnt/β-catenin signaling pathway has been reported to regulate crucial events during neoplasic development, such as cell differentiation, proliferation, invasion, migration, apoptosis, and angiogenesis. In this review, we will focus on microRNAs and long non-coding RNAs that have been implicated in gastric cancer tumorigenesis via modulation of the Wnt/β-catenin signaling pathway, which provided some biomarkers to prognosis, diagnosis, and therapy. View Full-Text
Keywords: non-coding RNAs; lncRNAs; microRNAs; Wnt pathway; gastric cancer non-coding RNAs; lncRNAs; microRNAs; Wnt pathway; gastric cancer
Show Figures

Figure 1

MDPI and ACS Style

Takao Real Karia, B.; Albuquerque Pinto, C.; Gigek, C.O.; Wisnieski, F.; Arruda Cardoso Smith, M. Non-Coding RNAs and Wnt/β-Catenin Signaling Pathway in Gastric Cancer: From EMT to Drug Resistance. Onco 2021, 1, 140-157. https://doi.org/10.3390/onco1020012

AMA Style

Takao Real Karia B, Albuquerque Pinto C, Gigek CO, Wisnieski F, Arruda Cardoso Smith M. Non-Coding RNAs and Wnt/β-Catenin Signaling Pathway in Gastric Cancer: From EMT to Drug Resistance. Onco. 2021; 1(2):140-157. https://doi.org/10.3390/onco1020012

Chicago/Turabian Style

Takao Real Karia, Bruno, Camila Albuquerque Pinto, Carolina O. Gigek, Fernanda Wisnieski, and Marilia Arruda Cardoso Smith. 2021. "Non-Coding RNAs and Wnt/β-Catenin Signaling Pathway in Gastric Cancer: From EMT to Drug Resistance" Onco 1, no. 2: 140-157. https://doi.org/10.3390/onco1020012

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop